

ASX RELEASE

Ellex Medical Lasers Ltd (ASX:ELX)

Adelaide, Australia

Date: 26 September 2013

Release: Immediate

Topic: **Ellex Secures US Government Qualification for SLT Glaucoma Laser Products**



---

**Adelaide, Australia, 26 September 2013** – Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that its portfolio of industry-leading SLT glaucoma lasers has been qualified for inclusion on its US Government Services Administration (GSA) contract. Effective 1 October 2013, the Company's SLT lasers can be sold to US government medical facilities in the USA and around the world.

Based on this qualification, the Ellex Tango™ SLT/YAG laser and Solo™ SLT laser will be added to the Company's current US GSA contract, which includes its range of cataract and retinal lasers, as well as its diagnostic ultrasound system.

According to Ellex CEO, Tom Spurling, the Company's updated GSA contract status offers a significant competitive advantage: "The GSA contract inclusion demonstrates to a potential US Government buyer that, along with our other products, Ellex is a responsible vendor of SLT lasers. We are now one of only two medical device manufacturers who can sell their SLT lasers to US government medical facilities. We are also the first manufacturer to be granted this status for SLT since the 8 July 2013 expiration of the SLT patent, which previously precluded our entry into the US market."

This milestone follows the launch of the Company's proprietary SLT technology into the US market in July 2013. Non-invasive and non-thermal, SLT is an advanced laser therapy for glaucoma. The second leading cause of blindness worldwide, glaucoma is estimated to affect more than 60 million people.\*

The US government will close its fiscal year on September 30, 2013. The updated contract will become valid on 1 October 2013, after which the Company expects to secure SLT sales to US government medical facilities.

*\*H A Quigley and A T Broman. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 March; 90(3): 262–267. doi: 10.1136/bjo.2005.081224)*

---

## ABOUT ELLEX

Ellex Medical Lasers Limited (ASX:ELX) is a pioneer in the development of medical technologies for the diagnosis and treatment of eye disease. Since 1985, Ellex has evolved from a manufacturing company of primarily OEM products to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany and Australia, and a network of distribution partners in more than 100 countries. Today, more than 20,000 Ellex laser and imaging systems are

used worldwide in the fight against blindness. In more recent times, Ellex has diversified its product range to include distribution of a number of complementary third-party ophthalmic products.

For additional information about Ellex and its products, please visit [www.ellex.com](http://www.ellex.com)

---

**For further information on Ellex, please contact:**

Tom Spurling, CEO  
Ellex Medical Lasers Limited  
82 Gilbert Street, Adelaide, SA, 5000  
W +61 8 8104 5293 | M +61 417 818 658  
[tspurling@ellex.com](mailto:tspurling@ellex.com)

Victor Previn, Chairman  
Ellex Medical Lasers Limited  
82 Gilbert Street, Adelaide, SA, 5000  
W +61 8 8104 5200 | M +61 414 661 994  
[vprevin@ellex.com](mailto:vprevin@ellex.com)

Maria Maieli, Company Secretary  
Ellex Medical Lasers Limited  
82 Gilbert Street, Adelaide, SA, 5000  
W +61 8 8104 5200  
[mmaieli@ellex.com](mailto:mmaieli@ellex.com)

**For media enquiries, please contact:**

Kate Hunt, Corporate Communications Manager  
Ellex Medical Lasers Limited  
82 Gilbert Street, Adelaide, SA, 5000  
W +61 8 8104 5214 | M +61 404 080 679  
[khunt@ellex.com](mailto:khunt@ellex.com)